On the stock market since 2017, it operates in the world of health and science. It has 29,400 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 17% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $1.6B. In times of high interest rates, a gap like that can squeeze a company.
The stock trades 53% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 21% a year on average.
The average analyst price target is $17.11 — 20% above today’s price.
The company’s market value is 1832 times its annual profit. Even a small disappointment could hit the price hard.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, RCM sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: RCM is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.